$ADXS climber $3.25 / $8.79 Nasdaq CM called

$ADXS climber $3.25 / $8.79
Nasdaq CM

called 6/4/14


Website

96% Buy Composite rating



Shares Outstanding: 19.52M
Float: 17.53M
% Held by Insiders: 9.11%
% Held by Institutions: 9.60%
Shares Short (as of Nov 28, 2014): 422.55K
Short Ratio (as of Nov 28, 2014): 3.30
Short % of Float (as of Nov 28, 2014): 2.30%
Shares Short (prior month): 444.58K



10-Q 9/9/14
Summary

Recent trades (4,828 Dec 30th)


Headlines

Tuesday, December 30, 2014
Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday HousecallGlobeNewswire (Tue 7:30AM EST)

Monday, December 29, 2014
Advaxis (ADXS) Stock Hits New 52-Week High on High Volumeat TheStreet (Mon, Dec 29)

Monday, December 22, 2014
ADVAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Mon, Dec 22)

Friday, December 19, 2014
Advaxis Completes $17 Million FinancingGlobeNewswire (Fri, Dec 19)

Wednesday, December 17, 2014
ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other EventsEDGAR Online (Wed, Dec 17)

Monday, December 15, 2014
ADXS: FDA Accepts Advaxis’s Investigational New Drug Application to Begin Clinical Trials of ADXS-HPV in Combination with MedImmune’s MEDI4736 in HPV-Associated CancersZacks Small Cap Research (Mon, Dec 15)
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated CancersGlobeNewswire (Mon, Dec 15)

Friday, December 12, 2014
Advaxis's Cancer Immunotherapies Featured on FOX NewsGlobeNewswire (Fri, Dec 12)

Thursday, December 11, 2014
Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature BiotechnologyGlobeNewswire (Thu, Dec 11)

Wednesday, December 10, 2014
ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other EventsEDGAR Online (Wed, Dec 10)

Monday, December 8, 2014
ADXS: FDA Clears Advaxis’s Investigational New Drug Application to Begin Clinical Trials of ADXS-PSA in Combination with Merck's pembrolizumab (KEYTRUDA) for Prostate CancerZacks Small Cap Research (Mon, Dec
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate CancerGlobeNewswire (Mon, Dec

Wednesday, December 3, 2014
InMed Pharma's Hiring of Tiberend Highlights Biotech FocusAccesswire (Wed, Dec 3)

Tuesday, November 25, 2014
Advaxis to Present at the LD Micro ConferenceGlobeNewswire (Tue, Nov 25)

Monday, November 24, 2014
MarketExclusive.com - Nobel Financial Reiterates Buy Rating of Advaxis, Inc. Based on a Review of Recent Data Presentations and IND SubmissionsAccesswire (Mon, Nov 24)
Advaxis, Inc. – “From Two Checkpoint Inhibitor Development Agreements to Two IND Filings in Four Months – A Special Thanks…”Accesswire (Mon, Nov 24)

Thursday, November 20, 2014
ADXS: New Jersey Technology Business Tax Program Grants Advaxis $1.7M Tax CreditZacks Small Cap Research (Thu, Nov 20)
Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) ProgramGlobeNewswire (Thu, Nov 20)

Wednesday, November 12, 2014
Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck CancerGlobeNewswire (Wed, Nov 12)

Wednesday, November 5, 2014
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate CancerGlobeNewswire (Wed, Nov 5)

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP